{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of PET-CT in Locally Advanced Esophageal Adenocarcinoma"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted at multiple centers."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults with locally advanced esophageal adenocarcinoma. Eligibility criteria included histologically confirmed adenocarcinoma and suitability for neoadjuvant therapy."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received PET-CT-adapted therapy, while the control group received standard care."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was progression-free survival over 24 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 98 in the intervention group and 97 in the control group, using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group showed improved progression-free survival (mean difference = 5.2 months, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in the intervention group and 1% in the control group experiencing gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by the National Cancer Institute."
      }
    },
    "total_score": 22,
    "max_score": 25
  },
  "model": "gpt-4o"
}